GTx, Inc. (NASDAQ:GTXI) insider Jason T. Shackelford sold 3,090 shares of the firm’s stock in a transaction on Friday, January 5th. The shares were sold at an average price of $11.33, for a total transaction of $35,009.70. Following the sale, the insider now owns 31,111 shares in the company, valued at $352,487.63. The sale was disclosed in a document filed with the SEC, which is available through the SEC website.
Shares of GTx, Inc. (GTXI) opened at $11.56 on Friday. The company has a market cap of $240.19, a price-to-earnings ratio of -6.61 and a beta of 1.77. GTx, Inc. has a 52-week low of $2.73 and a 52-week high of $13.35.
GTX (NASDAQ:GTXI) last announced its quarterly earnings results on Tuesday, November 14th. The biopharmaceutical company reported ($0.53) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.28) by ($0.25). equities analysts forecast that GTx, Inc. will post -1.61 EPS for the current year.
Hedge funds and other institutional investors have recently made changes to their positions in the business. Caxton Corp bought a new stake in GTX in the 3rd quarter valued at $531,000. Abingworth LLP bought a new stake in GTX in the 3rd quarter valued at $2,781,000. Finally, Bank of New York Mellon Corp bought a new stake in GTX in the 2nd quarter valued at $124,000. Institutional investors own 11.57% of the company’s stock.
ILLEGAL ACTIVITY WARNING: “GTx, Inc. (GTXI) Insider Jason T. Shackelford Sells 3,090 Shares” was published by Markets Daily and is the sole property of of Markets Daily. If you are reading this piece on another website, it was illegally stolen and reposted in violation of United States & international copyright and trademark law. The correct version of this piece can be viewed at https://www.themarketsdaily.com/2018/01/12/gtx-inc-gtxi-insider-jason-t-shackelford-sells-3090-shares.html.
GTx, Inc is a biopharmaceutical company focused on the discovery, development and commercialization of small molecules for the treatment of cancer, including treatments for breast and prostate cancer, and other medical conditions. The Company is engaged in the development of selective androgen receptor modulators (SARMs).
Receive News & Ratings for GTX Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GTX and related companies with MarketBeat.com's FREE daily email newsletter.